Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals EYLEA (2 mg) U.S. Net Product Sales YoY Growth by Quarter
EYLEA (2 mg) U.S. Net Product Sales YoY Growth (%) (%)
Regeneron Pharmaceuticals EYLEA (2 mg) U.S. Net Product Sales YoY Growth: -41.0% in Q3 2026, unchanged from a year earlier.
Where the Q3 2026 figure comes from
“Release Narrative Revenues (FY2026Q3): EYLEA ® - U.S. | 400 | 681 | (41 | %)”
Source: Form 8-K (exhibit991q32026.htm, filed 2026-10-30) ↗
Reported in Form 8-K (EX-99.1) Financial Results — Revenues Narrative Table.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals EYLEA (2 mg) U.S. Net Product Sales YoY Growth (%), quarterly Q3 2022–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rev-eylea-2mg-us-yoy
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?